AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharma, S.
Right arrow Articles by Surolia, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharma, S.
Right arrow Articles by Surolia, N.
Antimicrobial Agents and Chemotherapy, December 2003, p. 3859-3866, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3859-3866.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Triclosan as a Systemic Antibacterial Agent in a Mouse Model of Acute Bacterial Challenge

Shilpi Sharma,1 T. N. C. Ramya,1 Avadhesha Surolia,1* and Namita Surolia2*

Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012,1 Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560 064, India2

Received 16 October 2002/ Returned for modification 25 November 2002/ Accepted 18 August 2003

The upsurge of multiple-drug-resistant microbes warrants the development and/or use of effective antibiotics. Triclosan, though used in cosmetic and dermatological preparations for several decades, has not been used as a systemic antibacterial agent due to problems of drug administration. Here we report the striking efficacy of triclosan in a mouse model of acute systemic bacterial infection. Triclosan not only significantly extends the survival time of the infected mice, it also restores blood parameters and checks liver damage induced by the bacterial infection. We believe that the excellent safety track record of triclosan in topical use coupled with our findings qualifies triclosan as a candidate drug or lead compound for exploring its potential in experimental systems for treating systemic bacterial infections.

* Corresponding author. Mailing address for Avadhesha Surolia: Molecular Biophysics Unit, Indian Institute of Science, Bangalore 560 012, India. Phone: 91-80-2932389. Fax: 91-80-3600535. E-mail: surolia{at}mbu.iisc.ernet.in.

* Mailing address for Namita Surolia: Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560 064, India. Phone: 91-80-8462750. Fax: 91-80-8462766. E-mail: surolia{at}jncasr.ac.in.

Antimicrobial Agents and Chemotherapy, December 2003, p. 3859-3866, Vol. 47, No. 12
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.12.3859-3866.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.